Agilent Expands Oligonucleotide Manufacturing Capabilities With New Boulder Lab
Additional laboratory capacity supports development and scale-up of emerging oligonucleotide manufacturing technologies.
Agilent
Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy
Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.
Pharma’s Digital Transformation
Industry experts Michelangelo Canzoneri, Josef Trapl, Wolfgang Winter, Christian Woelbeling, and Thomas Zimmer – all members of ISPE’s Pharma 4.0 guide core team – explain the transformational challenges and critical success factors of the digital Pharma 4.0 journey.
Agilent to Buy Canadian CDMO Biovectra for $925 Million
Santa Clara, CA-based Agilent Technologies has signed a definitive agreement to acquire specialized contract development and manufacturing organization Biovectra from H.I.G. Capital in a move to expand its end-to-end biopharma solutions.
Abcam Attracts Interest from US Life Sciences Giants
Abcam, a biotech supplier, has garnered interest from major US life sciences companies Danaher and Agilent as it explores its potential sale. The company has also approached Germany’s Merck and attracted attention from large buyout firms, say sources of Bloomberg.
Agilent Contracts Turner for Frederick API Project
Agilent Technologies has selected Turner Construction to build its previously announced new API plant in Frederick, Colorado, USA. The project is scheduled for completion in 2026.
A Roadmap for Pharma 4.0
Industry experts Josef Trapl, Wolfgang Winter, Christian Woelbeling, and Thomas Zimmer – all members of ISPE’s Pharma 4.0 group – talk about the idea behind ISPE’s Pharma 4.0 initiative and the challenges on the way to realize the digital transformation of the pharmaceutical industry.
